Charco Neurotech

The CUE1 device novelly draws on two empirically evidenced key principles: vibrotactile stimulation and ‘cueing’, which, according to the scientific literature, can alleviate freezing of gait (FOG) and improve motor performance.

Commonly worn on the sternum, CUE1 delivers specialised vibrational patterns and pulses to improve patient symptoms, and participants in the company’s clinical tests have reported improvements in fine-motor tasks, walking and other movement.

CUE1’s development resulted from a $10 million seed investment led by Amadeus Capital Partners and Parkwalk Advisors. The company continues to enjoy an upsurge in global demand for its wearable device.

Career opportunities at Charco Neurotech